ReviewGene therapy2005
HSV trafficking and development of gene therapy vectors with applications in the nervous system.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 98 citations in OpenAlex.
- Gene therapy for polygenic or complex diseases.Biomarker research · 2024Review
- Nucleic acid-based drugs for patients with solid tumours.Nature reviews. Clinical oncology · 2024Review
- Enkephalin Rescues Temporomandibular Joint Pain-Related Behavior in Rats.Advances in neurobiology · 2024Article
- Viral vector-based gene therapies in the clinic.Bioengineering & translational medicine · 2022Review
- Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.Molecular neurobiology · 2022Review
- Viral Venereal Diseases of the Skin.American journal of clinical dermatology · 2021Review
- Rabies Virus Pseudotyped with CVS-N2C Glycoprotein as a Powerful Tool for Retrograde Neuronal Network Tracing.Neuroscience bulletin · 2020Article
- A Student's Guide to Neural Circuit Tracing.Frontiers in neuroscience · 2019Review
- Global Connectivity and Function of Descending Spinal Input Revealed by 3D Microscopy and Retrograde Transduction.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Approved Antiviral Drugs over the Past 50 Years.Clinical microbiology reviews · 2016Review
- Article
- Neuroanatomy goes viral!Frontiers in neuroanatomy · 2015Review
- An In Vitro HSV-1 Reactivation Model Containing Quiescently Infected PC12 Cells.BioResearch open access · 2013Article
- Quantification of HSV-1-mediated expression of the ferritin MRI reporter in the mouse brain.Gene therapy · 2013Article
- Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.Reviews in medical virology · 2013Review
- Axonal transport of adeno-associated viral vectors is serotype-dependent.Gene therapy · 2013Article
- Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.Frontiers in cellular neuroscience · 2013Article
- A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity.PloS one · 2013Article
- Anti-angiogenic gene therapy in the treatment of malignant gliomas.Neuroscience letters · 2012Review
- Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5.Gene therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 1 (HSV-1) is a neurotropic double-stranded DNA virus that causes cold sores, keratitis, and rarely encephalitis in humans. Nonpathogenic HSV-1 gene transfer vectors have been generated by elimination of viral functions necessary for replication. The life cycle of the native virus includes replication in epithelial cells at the site of initial inoculation followed by retrograde axonal transport to the nuclei of sensory neurons innervating the area of cutaneous primary infection. In this review, we summarize the current understanding of the molecular basis for HSV cell entry, nuclear transport of the genome, virion egress following replication, and retrograde and anterograde axonal transport in neurons. We discuss how each of these properties has been exploited or modified to allow the generation of gene transfer vectors with particular utility for neurological applications. Recent advances in engineering virus entry have provided proof of principle that vector targeting is possible. Furthermore, significant and potentially therapeutic modifications to the pathological responses to various noxious insults have been demonstrated in models of peripheral nerve disease. These applications exploit the natural axonal transport mechanism of HSV, allowing transgene expression in the cell nucleus within the inaccessible trigeminal ganglion or dorsal root ganglion, following the noninvasive procedure of subcutaneous vector inoculation. These findings demonstrate the importance of understanding basic virology in the design of vector systems and the powerful approach of exploiting favorable properties of the parent virus in the generation of gene transfer vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.